[Effectiveness and tolerability of amisulpride in patients with schizophrenia: results of a 6-month open study].
OBJECTIVE
6-month multicentre, observational, open study evaluated the efficacy and tolerability of the new generation antipsychotic drug amisulpride in patients with acute schizophrenia.


METHODS
99 patients were included in the study, 72 (72%) completed the 6-month observation.


RESULTS
Marked improvement in CGI after 6 months of treatment was observed in 56 (56%) patients. Therapy with amisulpride reduced both positive (20% reduction of positive symptoms in the PANSS positive subscale in 78%) and negative symptoms (20% reduction of negative symptoms in the PANSS negative subscale in 77%).


CONCLUSIONS
Amisulpride was well tolerated, adverse events responsible for premature withdrawal from the study were observed only in 6% patients.
Rzewuska
Małgorzata
M
Samodzielnej Pracowni Farmakoterapii IPiN w Warszawie.
Kuczyński
Wojciech
W
Luks
Małgorzata
M
D000328:Adult; D000368:Aged; D000077582:Amisulpride; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D011788:Quality of Life; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D013469:Sulpiride / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D013469:Sulpiride; D000077582:Amisulpride